Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Jo Shorthouse

Latest From Jo Shorthouse

Investment And Acquisition In Rare Diseases

In Vivo talks to investors, analysts and companies in rare disease about the challenges they face to innovate and to grow.

Rare Diseases M & A

Moving The Needle In Rare Disease: UCB’s gMG Strategy

Launching a novel drug into a new market is tough. UCB’s Kimberly Moran, talked to In Vivo about how being both patient and digital first gives the company a competitive commercial advantage in an increasingly growing market.

Rare Diseases Market Access

Win Big Or Lose Big: The Impact Of The Unified Patent Court

Decades after it was first mentioned, the updated European patent system – which includes the Unitary Patent and the Unified Patent Court – has finally materialized. What impact will this have on originator and generic pharma?

EU Legislative Reform Intellectual Property

Opportunities In Fertility: Recognizing Gaps In The Market

Ferring Pharmaceuticals’ US CSO Elizabeth Garner talks to In Vivo about the future of fertility and where investment should be heading to make a dent in this multi-million-dollar market.

Women's Health Gynecology & Urology

The Power Of AI To Map The Patient Journey

Mapping the patient journey uncovers a wealth of insights into care, diagnosis and intervention. The onset of advanced analytics tools and sensors now augment the pharma industry’s understanding of the challenges of traversing health care systems. Layering AI into the mapping process not only has the power to provide insights into the current clinical pathway, it can be used to predict and intervene in clinical care.

Artificial Intelligence Innovation

Parkinson’s Disease: Ripe For A Rethink

Despite decades of R&D, there are no disease modifying therapies on the market for Parkinson’s disease, and few efficacious products for non-motor symptoms. Clinical setbacks have been rife but breakthroughs in diagnostics and a better understanding of disease pathology brings hope for the future. In Vivo speaks to some of those responsible for bringing innovation to the field. 

Neurology Clinical Trials
See All
UsernamePublicRestriction

Register